ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
NCT07332975 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 77
Last updated 2026-05-01
Summary
This translational biomarker study will collect blood in patients Stage I triple negative breast cancer at diagnosis prior to either neoadjuvant treatment or surgery and then during treatment.
Conditions
Sponsors & Collaborators
-
University of Pittsburgh
lead OTHER
Principal Investigators
-
Marija Balic, MD · UPMC Hillman Cancer Center
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-01-20
- Primary Completion
- 2029-01-20
- Completion
- 2029-01-20
Countries
- United States
Study Locations
More Related Trials
-
Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China
NCT03792529 ·Status: UNKNOWN
-
Retrospective Comparative in Vitro Case-controlled Study of the Liquid Biopsy Test System in Women With Breast Cancer
NCT04927130 ·Status: UNKNOWN
-
Diagnostic Biomarkers Exploration of Breast Cancer From Serum and Urine
NCT06102018 ·Status: RECRUITING
-
Detecting Circulating Tumor Cells (CTCs) and Cell Free DNA (cfDNA) in Peripheral Blood of Breast Cancer (BC) Patients to Develop the Clinical Application for Early Detection and Diagnostics
NCT03511859 ·Status: UNKNOWN
-
Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy
NCT05649475 ·Status: UNKNOWN
-
Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery
NCT05914792 ·Status: ACTIVE_NOT_RECRUITING
-
ctDNA Monitoring in Early Breast Cancer
NCT04353557 ·Status: RECRUITING
-
Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer
NCT01514565 ·Status: UNKNOWN
-
Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer
NCT00897416 ·Status: COMPLETED
-
Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer
NCT03457779 ·Status: COMPLETED ·Phase: NA
-
Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
NCT05058183 ·Status: RECRUITING ·Phase: NA
-
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT05770531 ·Status: RECRUITING ·Phase: PHASE2
-
CtDNA Based MRD Testing for NAC Monitoring in TNBC
NCT06230185 ·Status: RECRUITING
-
Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer
NCT03260192 ·Status: RECRUITING
-
Study of Biomarkers in Tissue Samples From Patients With Breast Cancer
NCT01004796 ·Status: UNKNOWN
-
Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants
NCT05054010 ·Status: ACTIVE_NOT_RECRUITING
-
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT05528133 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer
NCT05079074 ·Status: COMPLETED
-
Triple-negative Breast Cancer: a New Perspective on Biomarkers
NCT03539965 ·Status: COMPLETED
-
Tracking Triple-negative Breast Cancer Evolution Through Therapy
NCT03077776 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm
NCT02266420 ·Status: COMPLETED ·Phase: NA
-
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
NCT05427617 ·Status: COMPLETED
-
Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients
NCT03881384 ·Status: UNKNOWN
-
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)
NCT03252717 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer
NCT03161834 ·Status: WITHDRAWN